health-and-medicine

Down 17%: Is Sarepta a Bad News Buy?

Duchenne muscular dystrophy, or DMD, drugmakers have been on a win streak lately, with Prosensa , Sarepta Therapeutics and PTC Therapeutics...

Is Pharmacyclics the Next Celgene?

Pharmacyclics has made a big move in the past two years as investors have become increasingly excited by the potential for Imbruvica,...

Why Zogenix Inc. Stock Tumbled

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in...

Why Mylan Should Buy Alkermes

A continuous stream of health care companies have made news headlines recently for M&A announcements. Most of these deals have allowed...